Haemolysis during sodium dimercaptosulphonate therapy for Wilson's disease in G6PD-deficient patients: First report of two cases

S Lai; Y Q Huang; A Q Liu; H W Wu

doi:10.1111/jcpt.12576

Haemolysis during sodium dimercaptosulphonate therapy for Wilson's disease in G6PD-deficient patients: First report of two cases

J Clin Pharm Ther. 2017 Dec;42(6):783-785. doi: 10.1111/jcpt.12576. Epub 2017 Jun 20.

Authors

S Lai^{1

2}, Y Q Huang³, A Q Liu³, H W Wu^{1

2}

Affiliations

¹ Department of Pharmacy, the First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
² Department of Clinical Pharmacy, Guangdong Pharmaceutical University, Guangzhou, China.
³ Department of Neurology, the First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.

PMID: 28635014
DOI: 10.1111/jcpt.12576

Abstract

What is known and objective: Wilson's disease (WD) is an inherited disorder in which defective biliary excretion of copper leads to its accumulation. Sodium dimercaptosulphonate (DMPS) is used as the primary therapy in China.

Case description: We report two cases, with WD and G6PD deficiency, who developed haemolysis on treatment with DMPS, without any other known risk. After withdrawal of DMPS and administration of dexamethasone and packed red blood cells, the patients recovered.

What is new and conclusion: Clinicians should keep in mind haemolysis as a potentially life-threatening side effect of DMPS in patients with G6PD.

Keywords: Wilson's disease; adverse effect; glucose-6-phosphate; haemolysis.

Publication types

Case Reports

MeSH terms

Adult
Glucosephosphate Dehydrogenase Deficiency / drug therapy*
Hemolysis / drug effects*
Hepatolenticular Degeneration / drug therapy*
Humans
Male
Unithiol / adverse effects*
Unithiol / therapeutic use*
Young Adult

Substances

Unithiol